Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1770170

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1770170

Human Growth Hormone Drugs

PUBLISHED:
PAGES: 335 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Human Growth Hormone Drugs Market to Reach US$5.2 Billion by 2030

The global market for Human Growth Hormone Drugs estimated at US$4.0 Billion in the year 2024, is expected to reach US$5.2 Billion by 2030, growing at a CAGR of 4.2% over the analysis period 2024-2030. Subcutaneous, one of the segments analyzed in the report, is expected to record a 4.7% CAGR and reach US$3.4 Billion by the end of the analysis period. Growth in the Intramuscular segment is estimated at 3.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.5 Billion While China is Forecast to Grow at 5.8% CAGR

The Human Growth Hormone Drugs market in the U.S. is estimated at US$1.5 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$358.1 Million by the year 2030 trailing a CAGR of 5.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.8% and 3.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.5% CAGR.

Global Human Growth Hormone Drugs Market - Key Trends and Drivers Summarized

Human Growth Hormone (HGH) drugs consist of synthetic forms of growth hormones used to treat various medical conditions caused by inadequate endogenous growth hormone production. These conditions include growth hormone deficiency in children, which can lead to stunted growth, and adult growth hormone deficiency, which may cause a variety of symptoms such as decreased muscle mass, energy, and quality of life. HGH is also used in treating Turner syndrome, Prader-Willi syndrome, and chronic renal insufficiency. Beyond these therapeutic uses, HGH has applications in improving muscle mass and performance, which has led to its controversial use in sports and aging-related treatments.

The market for HGH drugs has expanded significantly due to advancements in biotechnology that have improved the efficacy and safety of these drugs. The development of recombinant DNA technology has been a pivotal factor in enabling the mass production of safe and effective HGH, which closely mimics the natural growth hormone produced in the body. This has also helped reduce the occurrence of adverse reactions compared to earlier extracts from human pituitary glands, which were used before synthetic versions became available. Furthermore, enhancements in drug delivery systems, including the development of easier-to-use injectable pens and sustained-release formulations, have improved patient compliance and treatment outcomes. As research continues to unveil new potential applications of HGH, such as in recovery from major surgeries and burns, the scope of its therapeutic benefits continues to broaden.

The growth in the human growth hormone drugs market is driven by several factors, including an increase in the prevalence of conditions requiring HGH therapy, advancements in diagnostic techniques, and a better understanding of the role of HGH in various bodily functions. Improved diagnostic methods have led to more frequent identification of growth hormone deficiencies in both children and adults, which, in turn, boosts the demand for HGH treatments. Additionally, ongoing research and development efforts aimed at expanding the applications of HGH and improving drug delivery methods are significant contributors to market growth. Moreover, there is an increasing consumer awareness and acceptance of the benefits of HGH therapy in managing age-related conditions and improving overall health outcomes, which further stimulates market expansion. Regulatory approvals in new regions and for new indications also play a crucial role in the sustained growth of this market, facilitating the wider availability and adoption of HGH therapies globally.

SCOPE OF STUDY:

The report analyzes the Human Growth Hormone Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Route of Administration (Subcutaneous, Intramuscular, Intravenous, Oral); Distribution Channel (Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy, Online Pharmacy); Application (Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS), Other Applications)

Geographic Regions/Countries:

World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Spain; Russia; Rest of Europe; Asia-Pacific; Australia; India; South Korea; Rest of Asia-Pacific; Latin America; Argentina; Brazil; Mexico; Rest of Latin America; Middle East; Iran; Israel; Saudi Arabia; UAE; Rest of Middle East; Africa.

Select Competitors (Total 46 Featured) -

  • Eli Lilly and Company
  • EMD Serono, Inc.
  • Ambrx, Inc.
  • Ferring International Center SA
  • Hanmi Pharmaceuticals Co., Ltd.
  • Aileron Therapeutics, Inc.
  • Alteogen, Inc.
  • CinnaGen Co.
  • Genexine, Inc.
  • IPP Group Ltd.
  • BIOSIDUS SA
  • Corlison Pte. Limited
  • Access Pharmaceuticals
  • ERBAGIL srl
  • Kynerion S.r.l.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Show more
Product Code: MCP-7129

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Human Growth Hormone Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
    • A Prelude to Human Growth Hormones
    • Recombinant Human Growth Hormones
    • Evolution of Recombinant Human Growth Hormones (hGH)
  • GLOBAL MARKET OVERVIEW
    • Global Human Growth Hormone Drugs Market to Witness Steady Growth
    • List of Select Approved Prescription Daily-dose hGH Products by Indication
    • List of Select Approved Prescription Weekly-dose hGH Products by Indication
    • Subcutaneous Route Dominates Human Growth Hormone Drugs Market
    • Growth Hormone Deficiency Application Leads the Human Growth Hormone Drugs Market
    • North America and Europe Dominate, Asia-Pacific to Witness Fastest Growth
    • Market Restraints
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • High Prevalence of Growth Hormone Deficiency Disorders
    • Pediatric GHD Rules, while Adult GHD Remains Underserved
    • Worldwide Recombinant Human Growth Hormone Market by Indication (2020): Percentage Breakdown of Value Sales for Pediatric GHD; Adult GHD, Turner Syndrome & Idiopathic Short Stature; and Others
    • Long-Acting hGH Drugs - A Game Changer for the Human Growth Hormone Drugs Market
    • Approval of Novo Nordisk's Once-Weekly Sogroya to Transform the Market Landscape
    • Other Noteworthy Developments in the Long Acting hGH Space
    • Patent Expiry Paves Way for the Emergence of Biosimilars
    • Strong Innovation Drive Takes Hold of the hGH Industry
    • Manufacturers Bet on Novel Drug Delivery Technologies
    • Growing Non-Prescription/Off-Label Usage - A Potential Health Hazard
    • Needle-less Drug Delivery Systems to Wipe Out of Syringes
    • Drug Delivery Device Options for Marketed hGH Products
    • Major Growth Restraining Factors
    • Complex Delivery System
    • High Cost of hGH Treatment
    • Biosimilars Threaten Revenue Growth Erosion
  • PIPELINE ANALYSIS
    • Select Daily and Long-Acting Human Growth Hormone Products List in Phase III Pipeline
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Human Growth Hormone Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 3: World 15-Year Perspective for Human Growth Hormone Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Subcutaneous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Subcutaneous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 6: World 15-Year Perspective for Subcutaneous by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Intramuscular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Intramuscular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 9: World 15-Year Perspective for Intramuscular by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Intravenous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Intravenous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 12: World 15-Year Perspective for Intravenous by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 15: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 18: World 15-Year Perspective for Hospital Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Specialty Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Specialty Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 21: World 15-Year Perspective for Specialty Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 24: World 15-Year Perspective for Retail Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for Online Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 26: World Historic Review for Online Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 27: World 15-Year Perspective for Online Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 29: World Historic Review for Growth Hormone Deficiency by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 30: World 15-Year Perspective for Growth Hormone Deficiency by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 31: World Recent Past, Current & Future Analysis for Turner Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 32: World Historic Review for Turner Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 33: World 15-Year Perspective for Turner Syndrome by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 34: World Recent Past, Current & Future Analysis for Idiopathic Short Stature (ISS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 35: World Historic Review for Idiopathic Short Stature (ISS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 36: World 15-Year Perspective for Idiopathic Short Stature (ISS) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 37: World Recent Past, Current & Future Analysis for Prader-Willi Syndrome (PWS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 38: World Historic Review for Prader-Willi Syndrome (PWS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 39: World 15-Year Perspective for Prader-Willi Syndrome (PWS) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 40: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 41: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 42: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 43: World Human Growth Hormone Drugs Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Human Growth Hormone Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 44: USA Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: USA 15-Year Perspective for Human Growth Hormone Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intravenous and Oral for the Years 2015, 2025 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: USA 15-Year Perspective for Human Growth Hormone Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
    • TABLE 50: USA Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: USA Historic Review for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: USA 15-Year Perspective for Human Growth Hormone Drugs by Application - Percentage Breakdown of Value Sales for Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: Canada 15-Year Perspective for Human Growth Hormone Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intravenous and Oral for the Years 2015, 2025 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: Canada 15-Year Perspective for Human Growth Hormone Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
    • TABLE 59: Canada Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Canada Historic Review for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: Canada 15-Year Perspective for Human Growth Hormone Drugs by Application - Percentage Breakdown of Value Sales for Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications for the Years 2015, 2025 & 2030
  • JAPAN
    • Human Growth Hormone Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Japan 15-Year Perspective for Human Growth Hormone Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intravenous and Oral for the Years 2015, 2025 & 2030
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Japan 15-Year Perspective for Human Growth Hormone Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
    • TABLE 68: Japan Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Japan Historic Review for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Japan 15-Year Perspective for Human Growth Hormone Drugs by Application - Percentage Breakdown of Value Sales for Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications for the Years 2015, 2025 & 2030
  • CHINA
    • Human Growth Hormone Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 71: China Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: China 15-Year Perspective for Human Growth Hormone Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intravenous and Oral for the Years 2015, 2025 & 2030
    • TABLE 74: China Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: China Historic Review for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: China 15-Year Perspective for Human Growth Hormone Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
    • TABLE 77: China Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: China Historic Review for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: China 15-Year Perspective for Human Growth Hormone Drugs by Application - Percentage Breakdown of Value Sales for Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications for the Years 2015, 2025 & 2030
  • EUROPE
    • Human Growth Hormone Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Human Growth Hormone Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: Europe 15-Year Perspective for Human Growth Hormone Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: Europe 15-Year Perspective for Human Growth Hormone Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intravenous and Oral for the Years 2015, 2025 & 2030
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Europe 15-Year Perspective for Human Growth Hormone Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
    • TABLE 89: Europe Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Europe Historic Review for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Europe 15-Year Perspective for Human Growth Hormone Drugs by Application - Percentage Breakdown of Value Sales for Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications for the Years 2015, 2025 & 2030
  • FRANCE
    • Human Growth Hormone Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 92: France Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: France 15-Year Perspective for Human Growth Hormone Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intravenous and Oral for the Years 2015, 2025 & 2030
    • TABLE 95: France Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: France Historic Review for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: France 15-Year Perspective for Human Growth Hormone Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
    • TABLE 98: France Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: France Historic Review for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: France 15-Year Perspective for Human Growth Hormone Drugs by Application - Percentage Breakdown of Value Sales for Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications for the Years 2015, 2025 & 2030
  • GERMANY
    • Human Growth Hormone Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Germany 15-Year Perspective for Human Growth Hormone Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intravenous and Oral for the Years 2015, 2025 & 2030
    • TABLE 104: Germany Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Germany Historic Review for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Germany 15-Year Perspective for Human Growth Hormone Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
    • TABLE 107: Germany Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Germany Historic Review for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: Germany 15-Year Perspective for Human Growth Hormone Drugs by Application - Percentage Breakdown of Value Sales for Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: Italy 15-Year Perspective for Human Growth Hormone Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intravenous and Oral for the Years 2015, 2025 & 2030
    • TABLE 113: Italy Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Italy Historic Review for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: Italy 15-Year Perspective for Human Growth Hormone Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
    • TABLE 116: Italy Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Italy Historic Review for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: Italy 15-Year Perspective for Human Growth Hormone Drugs by Application - Percentage Breakdown of Value Sales for Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Human Growth Hormone Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 119: UK Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: UK 15-Year Perspective for Human Growth Hormone Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intravenous and Oral for the Years 2015, 2025 & 2030
    • TABLE 122: UK Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: UK Historic Review for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: UK 15-Year Perspective for Human Growth Hormone Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
    • TABLE 125: UK Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: UK Historic Review for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: UK 15-Year Perspective for Human Growth Hormone Drugs by Application - Percentage Breakdown of Value Sales for Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Spain 15-Year Perspective for Human Growth Hormone Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intravenous and Oral for the Years 2015, 2025 & 2030
    • TABLE 131: Spain Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Spain Historic Review for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Spain 15-Year Perspective for Human Growth Hormone Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
    • TABLE 134: Spain Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Spain Historic Review for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Spain 15-Year Perspective for Human Growth Hormone Drugs by Application - Percentage Breakdown of Value Sales for Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Russia 15-Year Perspective for Human Growth Hormone Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intravenous and Oral for the Years 2015, 2025 & 2030
    • TABLE 140: Russia Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Russia Historic Review for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Russia 15-Year Perspective for Human Growth Hormone Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
    • TABLE 143: Russia Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Russia Historic Review for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Russia 15-Year Perspective for Human Growth Hormone Drugs by Application - Percentage Breakdown of Value Sales for Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Rest of Europe 15-Year Perspective for Human Growth Hormone Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intravenous and Oral for the Years 2015, 2025 & 2030
    • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Rest of Europe Historic Review for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Rest of Europe 15-Year Perspective for Human Growth Hormone Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
    • TABLE 152: Rest of Europe Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Rest of Europe Historic Review for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Rest of Europe 15-Year Perspective for Human Growth Hormone Drugs by Application - Percentage Breakdown of Value Sales for Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Human Growth Hormone Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 15-Year Perspective for Human Growth Hormone Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intravenous and Oral for the Years 2015, 2025 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Asia-Pacific 15-Year Perspective for Human Growth Hormone Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
    • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Asia-Pacific Historic Review for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Asia-Pacific 15-Year Perspective for Human Growth Hormone Drugs by Application - Percentage Breakdown of Value Sales for Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Human Growth Hormone Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 164: Latin America Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Latin America Historic Review for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Latin America 15-Year Perspective for Human Growth Hormone Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intravenous and Oral for the Years 2015, 2025 & 2030
    • TABLE 167: Latin America Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Latin America Historic Review for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: Latin America 15-Year Perspective for Human Growth Hormone Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
    • TABLE 170: Latin America Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Latin America Historic Review for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: Latin America 15-Year Perspective for Human Growth Hormone Drugs by Application - Percentage Breakdown of Value Sales for Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Human Growth Hormone Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Human Growth Hormone Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intravenous and Oral for the Years 2015, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: Middle East 15-Year Perspective for Human Growth Hormone Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
    • TABLE 179: Middle East Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Middle East Historic Review for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Middle East 15-Year Perspective for Human Growth Hormone Drugs by Application - Percentage Breakdown of Value Sales for Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications for the Years 2015, 2025 & 2030
  • AFRICA
    • Human Growth Hormone Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 182: Africa Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Africa Historic Review for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Africa 15-Year Perspective for Human Growth Hormone Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intravenous and Oral for the Years 2015, 2025 & 2030
    • TABLE 185: Africa Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Africa Historic Review for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Africa 15-Year Perspective for Human Growth Hormone Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
    • TABLE 188: Africa Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Africa Historic Review for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: Africa 15-Year Perspective for Human Growth Hormone Drugs by Application - Percentage Breakdown of Value Sales for Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications for the Years 2015, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!